Single User License
INR 136060
Site License
INR 272120
Corporate User License
INR 408180

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Relapsed Multiple Myeloma-Pipeline Review, H1 2015

Relapsed Multiple Myeloma-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Relapsed Multiple Myeloma-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Relapsed Multiple Myeloma-Pipeline Review, H1 2015', provides an overview of the Relapsed Multiple Myeloma's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Relapsed Multiple Myeloma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsed Multiple Myeloma and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Relapsed Multiple Myeloma

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Relapsed Multiple Myeloma and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Relapsed Multiple Myeloma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Relapsed Multiple Myeloma pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Relapsed Multiple Myeloma

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Relapsed Multiple Myeloma pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 8

Introduction 9

Global Markets Direct Report Coverage 9

Relapsed Multiple Myeloma Overview 10

Therapeutics Development 11

Pipeline Products for Relapsed Multiple Myeloma-Overview 11

Pipeline Products for Relapsed Multiple Myeloma-Comparative Analysis 12

Relapsed Multiple Myeloma-Therapeutics under Development by Companies 13

Relapsed Multiple Myeloma-Therapeutics under Investigation by Universities/Institutes 17

Relapsed Multiple Myeloma-Pipeline Products Glance 18

Late Stage Products 18

Clinical Stage Products 19

Relapsed Multiple Myeloma-Products under Development by Companies 20

Relapsed Multiple Myeloma-Products under Investigation by Universities/Institutes 25

Relapsed Multiple Myeloma-Companies Involved in Therapeutics Development 26

4SC AG 26

AB Science 27

AbbVie Inc. 28

Acceleron Pharma, Inc. 29

Acetylon Pharmaceuticals, Inc. 30

Altor BioScience Corporation 31

Arno Therapeutics, Inc. 32

Array BioPharma Inc. 33

Astellas Pharma Inc. 34

Astex Pharmaceuticals, Inc. 35

Biotest AG 36

Bristol-Myers Squibb Company 37

Celgene Corporation 38

Cellectar Biosciences, Inc. 39

Chroma Therapeutics Ltd. 40

CureTech Ltd. 41

Curis, Inc. 42

Exelixis, Inc. 43

F. Hoffmann-La Roche Ltd. 44

GlaxoSmithKline plc 45

Immunomedics, Inc. 46

Johnson & Johnson 47

Karyopharm Therapeutics, Inc. 48

MedImmune, LLC 49

Merck & Co., Inc. 50

Millennium Pharmaceuticals, Inc. 51

MorphoSys AG 52

Novartis AG 53

Noxxon Pharma AG 54

Oncolytics Biotech Inc. 55

Oncopeptides AB 56

Onyx Pharmaceuticals, Inc. 57

Patrys Limited 58

Pfizer Inc. 59

Pharma Mar, S.A. 60

Pharmacyclics, Inc. 61

Prolexys Pharmaceuticals, Inc. 62

Sanofi 63

Sevion Therapeutics, Inc. 64

Stemline Therapeutics, Inc. 65

Sumitomo Dainippon Pharma Co., Ltd. 66

Synta Pharmaceuticals Corp. 67

Threshold Pharmaceuticals, Inc. 68

Vivolux AB 69

Relapsed Multiple Myeloma-Therapeutics Assessment 70

Assessment by Monotherapy Products 70

Assessment by Combination Products 71

Assessment by Target 72

Assessment by Mechanism of Action 77

Assessment by Route of Administration 81

Assessment by Molecule Type 83

Drug Profiles 85

4SC-202-Drug Profile 85

ACP-196-Drug Profile 87

afuresertib hydrochloride-Drug Profile 89

alisertib-Drug Profile 91

alpelisib-Drug Profile 95

ALT-801-Drug Profile 97

ALT-803-Drug Profile 99

amrubicin hydrochloride-Drug Profile 101

AR-42-Drug Profile 103

AT-7519-Drug Profile 105

AT-9283-Drug Profile 108

B-701-Drug Profile 110

bendamustine hydrochloride-Drug Profile 111

cabozantinib s-malate-Drug Profile 114

carfilzomib-Drug Profile 117

CB-5083-Drug Profile 121

CC-90002-Drug Profile 122

Cell Therapy to Target CD138 for Relapsed and Refractory Multiple Myeloma-Drug Profile 123

CHR-3996-Drug Profile 124

CUDC-907-Drug Profile 125

dalantercept-Drug Profile 127

daratumumab-Drug Profile 129

dasatinib-Drug Profile 132

DKN-01-Drug Profile 135

elotuzumab-Drug Profile 137

erismodegib-Drug Profile 139

evofosfamide-Drug Profile 142

filanesib-Drug Profile 149

ganetespib-Drug Profile 151

GSK-2857916-Drug Profile 156

GSK-525762-Drug Profile 157

I131-CLR1404-Drug Profile 158

ibrutinib-Drug Profile 160

indatuximab ravtansine-Drug Profile 166

isatuximab-Drug Profile 168

ixazomib citrate-Drug Profile 170

LCL-161-Drug Profile 173

LGH-447-Drug Profile 175

linsitinib-Drug Profile 176

marizomib-Drug Profile 178

masitinib-Drug Profile 180

MEDI-551-Drug Profile 183

Melflufen-Drug Profile 185

milatuzumab-Drug Profile 187

MLN-0128-Drug Profile 189

MOR-202-Drug Profile 191

MV-NIS-Drug Profile 193

olaptesed pegol-Drug Profile 195

oprozomib-Drug Profile 198

palbociclib-Drug Profile 200

panobinostat-Drug Profile 204

PATSM-6-Drug Profile 210

pelareorep-Drug Profile 212

pembrolizumab-Drug Profile 217

pidilizumab-Drug Profile 223

plerixafor-Drug Profile 225

plitidepsin-Drug Profile 227

pomalidomide-Drug Profile 229

PRLX-93936-Drug Profile 233

quisinostat-Drug Profile 235

Recombinant Protein for Oncology-Drug Profile 237

ricolinostat-Drug Profile 239

selinexor-Drug Profile 241

SL-401-Drug Profile 245

SNS-01T-Drug Profile 247

trametinib dimethyl sulfoxide + uprosertib-Drug Profile 248

ulocuplumab-Drug Profile 250

urelumab-Drug Profile 252

vemurafenib-Drug Profile 254

venetoclax-Drug Profile 258

VLX-1570-Drug Profile 261

vorinostat-Drug Profile 262

Relapsed Multiple Myeloma-Recent Pipeline Updates 266

Relapsed Multiple Myeloma-Dormant Projects 418

Relapsed Multiple Myeloma-Discontinued Products 421

Relapsed Multiple Myeloma-Product Development Milestones 422

Featured News & Press Releases 422

Appendix 432

Methodology 432

Coverage 432

Secondary Research 432

Primary Research 432

Expert Panel Validation 432

Contact Us 432

Disclaimer 433

List of Tables

Number of Products under Development for Relapsed Multiple Myeloma, H1 2015 16

Number of Products under Development for Relapsed Multiple Myeloma-Comparative Analysis, H1 2015 17

Number of Products under Development by Companies, H1 2015 18

Number of Products under Development by Companies, H1 2015 (Contd..1) 19

Number of Products under Development by Companies, H1 2015 (Contd..2) 20

Number of Products under Development by Companies, H1 2015 (Contd..3) 21

Number of Products under Investigation by Universities/Institutes, H1 2015 22

Comparative Analysis by Late Stage Development, H1 2015 23

Comparative Analysis by Clinical Stage Development, H1 2015 24

Products under Development by Companies, H1 2015 25

Products under Development by Companies, H1 2015 (Contd..1) 26

Products under Development by Companies, H1 2015 (Contd..2) 27

Products under Development by Companies, H1 2015 (Contd..3) 28

Products under Development by Companies, H1 2015 (Contd..4) 29

Products under Investigation by Universities/Institutes, H1 2015 30

Relapsed Multiple Myeloma-Pipeline by 4SC AG, H1 2015 31

Relapsed Multiple Myeloma-Pipeline by AB Science, H1 2015 32

Relapsed Multiple Myeloma-Pipeline by AbbVie Inc., H1 2015 33

Relapsed Multiple Myeloma-Pipeline by Acceleron Pharma, Inc., H1 2015 34

Relapsed Multiple Myeloma-Pipeline by Acetylon Pharmaceuticals, Inc., H1 2015 35

Relapsed Multiple Myeloma-Pipeline by Altor BioScience Corporation, H1 2015 36

Relapsed Multiple Myeloma-Pipeline by Arno Therapeutics, Inc., H1 2015 37

Relapsed Multiple Myeloma-Pipeline by Array BioPharma Inc., H1 2015 38

Relapsed Multiple Myeloma-Pipeline by Astellas Pharma Inc., H1 2015 39

Relapsed Multiple Myeloma-Pipeline by Astex Pharmaceuticals, Inc., H1 2015 40

Relapsed Multiple Myeloma-Pipeline by Biotest AG, H1 2015 41

Relapsed Multiple Myeloma-Pipeline by Bristol-Myers Squibb Company, H1 2015 42

Relapsed Multiple Myeloma-Pipeline by Celgene Corporation, H1 2015 43

Relapsed Multiple Myeloma-Pipeline by Cellectar Biosciences, Inc., H1 2015 44

Relapsed Multiple Myeloma-Pipeline by Chroma Therapeutics Ltd., H1 2015 45

Relapsed Multiple Myeloma-Pipeline by CureTech Ltd., H1 2015 46

Relapsed Multiple Myeloma-Pipeline by Curis, Inc., H1 2015 47

Relapsed Multiple Myeloma-Pipeline by Exelixis, Inc., H1 2015 48

Relapsed Multiple Myeloma-Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 49

Relapsed Multiple Myeloma-Pipeline by GlaxoSmithKline plc, H1 2015 50

Relapsed Multiple Myeloma-Pipeline by Immunomedics, Inc., H1 2015 51

Relapsed Multiple Myeloma-Pipeline by Johnson & Johnson, H1 2015 52

Relapsed Multiple Myeloma-Pipeline by Karyopharm Therapeutics, Inc., H1 2015 53

Relapsed Multiple Myeloma-Pipeline by MedImmune, LLC, H1 2015 54

Relapsed Multiple Myeloma-Pipeline by Merck & Co., Inc., H1 2015 55

Relapsed Multiple Myeloma-Pipeline by Millennium Pharmaceuticals, Inc., H1 2015 56

Relapsed Multiple Myeloma-Pipeline by MorphoSys AG, H1 2015 57

Relapsed Multiple Myeloma-Pipeline by Novartis AG, H1 2015 58

Relapsed Multiple Myeloma-Pipeline by Noxxon Pharma AG, H1 2015 59

Relapsed Multiple Myeloma-Pipeline by Oncolytics Biotech Inc., H1 2015 60

Relapsed Multiple Myeloma-Pipeline by Oncopeptides AB, H1 2015 61

Relapsed Multiple Myeloma-Pipeline by Onyx Pharmaceuticals, Inc., H1 2015 62

Relapsed Multiple Myeloma-Pipeline by Patrys Limited, H1 2015 63

Relapsed Multiple Myeloma-Pipeline by Pfizer Inc., H1 2015 64

Relapsed Multiple Myeloma-Pipeline by Pharma Mar, S.A., H1 2015 65

Relapsed Multiple Myeloma-Pipeline by Pharmacyclics, Inc., H1 2015 66

Relapsed Multiple Myeloma-Pipeline by Prolexys Pharmaceuticals, Inc., H1 2015 67

Relapsed Multiple Myeloma-Pipeline by Sanofi, H1 2015 68

Relapsed Multiple Myeloma-Pipeline by Sevion Therapeutics, Inc., H1 2015 69

Relapsed Multiple Myeloma-Pipeline by Stemline Therapeutics, Inc., H1 2015 70

Relapsed Multiple Myeloma-Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2015 71

Relapsed Multiple Myeloma-Pipeline by Synta Pharmaceuticals Corp., H1 2015 72

Relapsed Multiple Myeloma-Pipeline by Threshold Pharmaceuticals, Inc., H1 2015 73

Relapsed Multiple Myeloma-Pipeline by Vivolux AB, H1 2015 74

Assessment by Monotherapy Products, H1 2015 75

Assessment by Combination Products, H1 2015 76

Number of Products by Stage and Target, H1 2015 78

Number of Products by Stage and Mechanism of Action, H1 2015 83

Number of Products by Stage and Route of Administration, H1 2015 87

Number of Products by Stage and Molecule Type, H1 2015 89

Relapsed Multiple Myeloma Therapeutics-Recent Pipeline Updates, H1 2015 271

Relapsed Multiple Myeloma-Dormant Projects, H1 2015 423

Relapsed Multiple Myeloma-Dormant Projects (Contd..1), H1 2015 424

Relapsed Multiple Myeloma-Dormant Projects (Contd..2), H1 2015 425

Relapsed Multiple Myeloma-Discontinued Products, H1 2015 426

List of Figures

Number of Products under Development for Relapsed Multiple Myeloma, H1 2015 16

Number of Products under Development for Relapsed Multiple Myeloma-Comparative Analysis, H1 2015 17

Number of Products under Development by Companies, H1 2015 18

Comparative Analysis by Late Stage Development, H1 2015 23

Comparative Analysis by Clinical Stage Development, H1 2015 24

Assessment by Monotherapy Products, H1 2015 75

Number of Products by Top 10 Targets, H1 2015 77

Number of Products by Stage and Top 10 Targets, H1 2015 77

Number of Products by Top 10 Mechanism of Actions, H1 2015 82

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 82

Number of Products by Top 10 Routes of Administration, H1 2015 86

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 86

Number of Products by Top 10 Molecule Types, H1 2015 88

Number of Products by Stage and Top 10 Molecule Types, H1 2015 88

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

4SC AG

AB Science

AbbVie Inc.

Acceleron Pharma, Inc.

Acetylon Pharmaceuticals, Inc.

Altor BioScience Corporation

Arno Therapeutics, Inc.

Array BioPharma Inc.

Astellas Pharma Inc.

Astex Pharmaceuticals, Inc.

Biotest AG

Bristol-Myers Squibb Company

Celgene Corporation

Cellectar Biosciences, Inc.

Chroma Therapeutics Ltd.

CureTech Ltd.

Curis, Inc.

Exelixis, Inc.

F. Hoffmann-La Roche Ltd.

GlaxoSmithKline plc

Immunomedics, Inc.

Johnson & Johnson

Karyopharm Therapeutics, Inc.

MedImmune, LLC

Merck & Co., Inc.

Millennium Pharmaceuticals, Inc.

MorphoSys AG

Novartis AG

Noxxon Pharma AG

Oncolytics Biotech Inc.

Oncopeptides AB

Onyx Pharmaceuticals, Inc.

Patrys Limited

Pfizer Inc.

Pharma Mar, S.A.

Pharmacyclics, Inc.

Prolexys Pharmaceuticals, Inc.

Sanofi

Sevion Therapeutics, Inc.

Stemline Therapeutics, Inc.

Sumitomo Dainippon Pharma Co., Ltd.

Synta Pharmaceuticals Corp.

Threshold Pharmaceuticals, Inc.

Vivolux AB

Relapsed Multiple Myeloma Therapeutic Products under Development, Key Players in Relapsed Multiple Myeloma Therapeutics, Relapsed Multiple Myeloma Pipeline Overview, Relapsed Multiple Myeloma Pipeline, Relapsed Multiple Myeloma Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com